01.12.2017 10:23

First IPO Day broke down barriers

For 15 years an IPO didn’t seem to be a viable option for Swiss start-ups. But this is slowly changing. At the first Swiss IPO Day held this week in Zurich Swiss start-ups met with investment bankers and advisors and received answers to their burning questions. 


10.11.2017 12:00

"An IPO has become a serious alternative”

On 28 November the first Swiss IPO Day will take place in Zurich organised by Swiss Startup Invest. At the event high-tech companies with high potential will meet the relevant investment bankers and advisors. We talked with Jean-Pierre Vuilleumier, Managing Director of Swiss Startup Invest, about the event and IPOs in general.


04.09.2017 14:16

Euronext expands to Switzerland

Swiss companies including Geneuro and Genkyotex went public recently at Euronext. Now Euronext launches a European Tech SME initiative, opening offices in four new countries – Germany, Italy, Spain and Switzerland –  and deploying teams on the ground to work collaboratively with local ecosystems.


12.04.2017 11:43

Schweizer Börse in Rücklage

Während China boomt und die USA in Sachen Börsengänge wieder aufholt, ziehen Schweizer Technologieunternehmen ausländische Börsenplätze vor. Dies zeigt eine aktuelle Auswertung des Beratungsunternehmens EY.


20.03.2017 09:10

Symetis launches its IPO on Euronext Paris

Symetis develops, produces and markets heart valve replacement solutions for the treatment of severe cardiac valve conditions. The company plans to raise € 55.8 million that could be increased to approximately € 64.1 million in the event of full exercise of the Overallotment Option. It's already the third younger Swiss technology company going public this year.


02.03.2017 11:00

GenKyoTex now listed on Euronext

Genticel and GenKyoTex announce that Genticel’s shareholders approved the resolutions implementing the strategic combination between the two companies. This transaction will result in the creation of a listed Franco-Swiss company called “Genkyotex” whose activity is principally devoted to the development of a pipeline of NOX inhibitors, a new therapeutic class in fibrosis and inflammatory pain.

Show All


23.02.2018 17:00 - 25.02.2018 17:00

Startup Weekend Lausanne Rolex Learning Center 1015 Ecublens

Show All


Monday, 19th March 2018; 16:00-19:00

How to Start a Company in Switzerland EPFL Innovation Park, Building C, North Entrance, 1st Floor, Room Neptune

Top viewed

Show All





Surprises for and from start-ups